% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Schweitzer:1018540,
      author       = {Schweitzer, Finja and Laurent, Sarah and Cortese, Irene and
                      Fink, Gereon Rudolf and Silling, Steffi and Skripuletz,
                      Thomas and Metz, Imke and Wattjes, Mike P. and Warnke,
                      Clemens},
      title        = {{P}rogressive {M}ultifocal {L}eukoencephalopathy},
      journal      = {Neurology},
      volume       = {101},
      number       = {16},
      issn         = {0028-3878},
      address      = {[Erscheinungsort nicht ermittelbar]},
      publisher    = {Ovid},
      reportid     = {FZJ-2023-04868},
      pages        = {700 - 713},
      year         = {2023},
      abstract     = {JC polyomavirus (JCV) establishes an asymptomatic latent
                      and/or persistent infection in most of the adult population.
                      However, in immunocompromised individuals, JCV can cause a
                      symptomatic infection of the brain, foremost progressive
                      multifocal leukoencephalopathy (PML). In the past 2 decades,
                      there has been increasing concern among patients and the
                      medical community because PML was observed as an adverse
                      event in individuals treated with modern (selective) immune
                      suppressive treatments for various immune-mediated diseases,
                      especially multiple sclerosis. It became evident that this
                      devastating complication also needs to be considered beyond
                      the patient populations historically at risk, including
                      those with hematologic malignancies or HIV-infected
                      individuals. We review the clinical presentation of PML, its
                      variants, pathogenesis, and current diagnostic approaches.
                      We further discuss the need to validate JCV-directed
                      interventions and highlight current management strategies
                      based on early diagnosis and restoring JCV-specific cellular
                      immunity, which is crucial for viral clearance and survival.
                      Finally, we discuss the importance of biomarkers for
                      diagnosis and response to therapy, instrumental in defining
                      sensitive study end points for successful clinical trials of
                      curative or preventive therapeutics. Advances in
                      understanding PML pathophysiology, host and viral genetics,
                      and diagnostics in conjunction with novel immunotherapeutic
                      approaches indicate that the time is right to design and
                      perform definitive trials to develop preventive options and
                      curative therapy for JCV-associated diseases.},
      cin          = {INM-3},
      ddc          = {610},
      cid          = {I:(DE-Juel1)INM-3-20090406},
      pnm          = {5251 - Multilevel Brain Organization and Variability
                      (POF4-525)},
      pid          = {G:(DE-HGF)POF4-5251},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {37487750},
      UT           = {WOS:001158672700001},
      doi          = {10.1212/WNL.0000000000207622},
      url          = {https://juser.fz-juelich.de/record/1018540},
}